T2M-010 

T2M-010 is a potent, brain-penetrant TREM2 agonist (K_d = 0.83 μM). T2M-010 activates receptor-proximal signaling, inducing SYK phosphorylation in TREM2-expressing cells, and promotes microglial phagocytosis. T2M-010 can be used for the study of protective microglial responses relevant to Alzheimer’s disease (AD)^[1].

T2M010 (25 µM, 1 h) leads to a robust twofold increase in SYK phosphorylation in HEK–hTREM2/DAP12 cells^[1].
T2M-010 (25 µM, 30 min) significantly enhances bead uptake in BV2 cells, demonstrating a marked increase in phagocytic activity[1]. T2M-010 shows no cytotoxicity in human fibroblasts (WI-38 and HS-27; IC₅₀ >100 µM), low hERG risk (IC₅₀ > 60 µM), and minimal inhibition of major CYP isoforms at 10 µM (≤ 11.2%)^[1].
T2M-010 can return robust A→B transport in MDCK– MDR1 assays (Papp = 2.85 × 10⁻⁵ cm/s) and a low efflux ratio (E_R = 1.07), pointing to minimal P-gp–mediated efflux^[1].
T2M-010 displays good gastrointestinal stability (> 88-86% parent remaining after 2 h in simulated gastric and intestinal fluids, respectively) and long plasma half-lives (167 min in mouse; 214 min in human)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

319.42

C₁₉H₁₇N₃S

364611-21-2

C1(CCNC2=NC(C3=CNC4=C3C=CC=C4)=CS2)=CC=CC=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cho S, et al. AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial Activity. bioRxiv [Preprint]. 2025 Sep 17:2025.09.11.675743.